News
LPCN
5.27
-3.13%
-0.17
Weekly Report: what happened at LPCN last week (0408-0412)?
Weekly Report · 5d ago
LPCN, ADIL and CADL among pre-market losers
Seeking Alpha · 04/12 12:32
BUZZ-U.S. STOCKS ON THE MOVE-Rent the Runway, Lumen Technologies, Enliven Therapeutics
The Dow Jones Industrial Average was up 0.02% on Thursday. The benchmark S&P 500 and the Dow were muted as long-dated Treasury yields remained elevated. Rent the Runway, Lumen Technologies, Enliven Therapeutics were among the top stocks on the NYSE.
Reuters · 04/11 18:05
BUZZ-U.S. STOCKS ON THE MOVE-Constellation Brands, Nike, Rocket Lab
The benchmark S&P 500 and the Nasdaq gained on Thursday. Producer prices data soothed investor jitters about sticky inflation. The Dow Jones Industrial Average was down 0.36% in the morning. Constellation Brands, Nike, Rocket Lab and Domino's Pizza are among the stocks on the move.
Reuters · 04/11 16:07
BUZZ-U.S. STOCKS ON THE MOVE-DoorDash, Devon Energy, Arvinas
DoorDash, Devon Energy, Arvinas among top Nasdaq percentage gainers. Softer-than-anticipated producer prices data soothed investor fears about sticky inflation. Dow e-minis were up 0.08% in premarket trading. The Nasdaq eyed a higher open on Thursday.
Reuters · 04/11 13:39
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Eliem Therapeutics (NASDAQ:ELYM) stock moved upwards by 51.6% to $4.05 during Thursday's pre-market session. Rallybio stock increased by 49.07% and Alpine Immune Sciences stock rose 36.62% during the same period.
Benzinga · 04/11 12:10
BUZZ-Lipocine up after drug improves fat-free mass in obesity patients in trial
Lipocine up after drug improves fat-free mass in obesity patients in trial. Shares of Lipocine LPCN.O up 5.1% to $6.8 premarket. Company says drug candidate increased fat free mass in patients by 6.7% in mid-stage trial.
Reuters · 04/11 12:10
Lipocine Reports Positive Phase 2 Results For LPCN 2401 In Participants With Obesity
NASDAQ · 04/11 11:42
LIPOCINE SHARES UP 11.8% PREMARKET AFTER CO'S EXPERIMENTAL DRUG IMPROVED BODY COMPOSITION IN OBESITY PATIENTS IN TRIAL
Reuters · 04/11 11:40
LIPOCINE INC: LPCN 2401 WELL-TOLERATED, ADVERSE EVENTS (AES) SIMILAR TO PLACEBO
Reuters · 04/11 11:00
Weekly Report: what happened at LPCN last week (0401-0405)?
Weekly Report · 04/08 09:38
Weekly Report: what happened at LPCN last week (0325-0329)?
Weekly Report · 04/01 09:37
Weekly Report: what happened at LPCN last week (0318-0322)?
Weekly Report · 03/25 09:39
Weekly Report: what happened at LPCN last week (0311-0315)?
Weekly Report · 03/18 09:38
12 Health Care Stocks Moving In Wednesday's After-Market Session
Molina Healthcare (NYSE:MOH) stock moved upwards by 24.2% to $503.11 during Wednesday's after-market session. The company's market cap stands at $29.3 billion. Evoke Pharma (NASDAQ:EVOK) shares rose 18.54% and Aptorum Gr stock rose 11.75% during the session. Losers Spruce Biosciences and Bright Green stock declined by 75.2%.
Benzinga · 03/13 21:32
Weekly Report: what happened at LPCN last week (0304-0308)?
Weekly Report · 03/11 09:37
LPCN Stock Earnings: Lipocine Beats EPS for Q4 2023
Lipocine reported earnings per share of -42 cents. The company reported revenue of $216,188. Lipocine was above the analyst estimate for EPS of -47 cents. The company's stock was down 2% after the market closed on Wednesday.
Investorplace · 03/07 19:52
Lipocine GAAP EPS of -$3.14
Seeking Alpha · 03/07 16:17
Press Release: Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 and provides a corporate update. Lipocine is a biopharmaceutical company focused on treating Central Nervous System disorders. The company announced positive results from a pilot study of LPCN 1154 for postpartum depression.
Dow Jones · 03/07 13:00
More
Webull provides a variety of real-time LPCN stock news. You can receive the latest news about Lipocine Inc through multiple platforms. This information may help you make smarter investment decisions.
About LPCN
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. It is exploring partnering opportunities for LPCN 1107, for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, for treatment of non-cirrhotic NASH. Its product candidate, TLANDO, an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.